Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Robert L. Jilka, … , A. Michael Parfitt, Stavros C. Manolagas
Robert L. Jilka, … , A. Michael Parfitt, Stavros C. Manolagas
Published August 15, 1999
Citation Information: J Clin Invest. 1999;104(4):439-446. https://doi.org/10.1172/JCI6610.
View: Text | PDF
Article Article has an altmetric score of 6

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

  • Text
  • PDF
Abstract

The mass of regenerating tissues, such as bone, is critically dependent on the number of executive cells, which in turn is determined by the rate of replication of progenitors and the life-span of mature cells, reflecting the timing of death by apoptosis. Bone mass can be increased by intermittent parathyroid hormone (PTH) administration, but the mechanism of this phenomenon has remained unknown. We report that daily PTH injections in mice with either normal bone mass or osteopenia due to defective osteoblastogenesis increased bone formation without affecting the generation of new osteoblasts. Instead, PTH increased the life-span of mature osteoblasts by preventing their apoptosis — the fate of the majority of these cells under normal conditions. The antiapoptotic effect of PTH was sufficient to account for the increase in bone mass, and was confirmed in vitro using rodent and human osteoblasts and osteocytes. This evidence provides proof of the basic principle that the work performed by a cell population can be increased by suppression of apoptosis. Moreover, it suggests novel pharmacotherapeutic strategies for osteoporosis and, perhaps, other pathologic conditions in which tissue mass diminution has compromised functional integrity.

Authors

Robert L. Jilka, Robert S. Weinstein, Teresita Bellido, Paula Roberson, A. Michael Parfitt, Stavros C. Manolagas

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1997 1988 Total
Citations: 5 9 14 13 30 25 29 24 38 25 31 26 33 27 53 42 34 38 47 46 42 39 37 25 36 14 3 1 1 787
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2016 (25)

Title and authors Publication Year
Osteocytic signalling pathways as therapeutic targets for bone fragility
LI Plotkin, T Bellido
Nature Reviews Endocrinology 2016
Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation
C Vrahnas, TA Pearson, AR Brunt, MR Forwood, KR Bambery, MJ Tobin, TJ Martin, NA Sims
Bone 2016
Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement
JA Siddiqui, NC Partridge
Physiology (Bethesda, Md.) 2016
Second generation sequencing of microRNA in Human Bone Cells treated with Parathyroid Hormone or Dexamethasone
N Laxman, CJ Rubin, H Mallmin, O Nilsson, C Tellgren-Roth, A Kindmark
Bone 2016
Suppression of p38α MAPK Signaling in Osteoblast Lineage Cells Impairs Bone Anabolic Action of Parathyroid Hormone: p38α IS REQUIRED FOR PTH OSTEOANABOLISM
C Thouverey, J Caverzasio
Journal of Bone and Mineral Research 2016
Cell Death in Chondrocytes, Osteoblasts, and Osteocytes
T Komori
International journal of molecular sciences 2016
Fibroblast Growth Factor Receptor 3 Deficiency Does Not Impair the Osteoanabolic Action of Parathyroid Hormone on Mice
Y Xie, L Yi, T Weng, J Huang, F Luo, W Jiang, CJ Xian, X Du, L Chen
International journal of biological sciences 2016
The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures
DA Houston, K Myers, VE MacRae, KA Staines, C Farquharson
Calcified Tissue International 2016
MODEL-BASED ANALYSIS OF IGF-1 EFFECT ON OSTEOBLAST AND OSTEOCLAST REGULATION IN BONE TURNOVER
WH Lee, MR Okos
Journal of Biological Systems 2016
Osteoporosis in Older Persons
JA Cauley
Osteoporosis in Older Persons 2016
Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
JW Park, SR Hwang, DH Seo, Y Byun
International Journal of Nanomedicine 2016
Overexpression of BCLXL in Osteoblasts Inhibits Osteoblast Apoptosis and Increases Bone Volume and Strength: BCLXL OVEREXPRESSION INCREASES BONE WITH STRENGTH
T Moriishi, R Fukuyama, T Miyazaki, T Furuichi, M Ito, T Komori
Journal of Bone and Mineral Research 2016
Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner
G Pellegrini, C Morales, T Wallace, L Plotkin, T Bellido
Nutrients 2016
Safety issues and adverse reactions with osteoporosis management
M Rossini, G Adami, S Adami, O Viapiana, D Gatti
Expert Opinion on Drug Safety 2016
Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis
L López-Delgado, L Riancho-Zarrabeitia, JA Riancho
Expert Opinion on Drug Metabolism & Toxicology 2016
Osteogenic potential of laser modified and conditioned titanium zirconium surfaces
P. David Charles, Ponsekar Abraham Anandapandian, Shila Samuel
Journal of Indian Prosthodontic Society 2016
Intermittent parathyroid hormone (1-34) application regulates cAMP-response element binding protein activity to promote the proliferation and osteogenic differentiation of bone mesenchymal stromal cells, via the cAMP/PKA signaling pathway
B Chen, T Lin, X Yang, Y Li, D Xie, H Cui
Experimental and therapeutic medicine 2016
N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction: N-cadherin restrains PTH repressive effects on sclerostin/SOST expression
H Yang, J Dong, W Xiong, Z Fang, H Guan, F Li
Annals of the New York Academy of Sciences 2016
Ostéoporose pendant la ménopause
A Khan, M Fortier
Journal of Obstetrics and Gynaecology Canada 2016
Intermittent administration of human parathyroid hormone (1–34) increases fixation of strontium-doped hydroxyapatite coating titanium implants via electrochemical deposition in ovariectomized rat femur
ZS Tao, WS Zhou, Z Qiang, K Tu, ZL Huang, HM Xu, T Sun, YX Lv, W Cui, L Yang
Journal of Biomaterials Applications 2016
Tratamento da osteoporose pós‐menopáusica: um algoritmo baseado na literatura para uso no sistema público de saúde
EL Caires, MC Bezerra, AF de Junqueira, SM de Fontenele, SC de Andrade, CB dAlva
Revista brasileira de reumatologia 2016
Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases
TJ Martin
Physiological reviews 2016
Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review
PK Suen, L Qin
Journal of Orthopaedic Translation 2016
Osteoporosis in Orthopedics
Y Shimada, N Miyakoshi
2016
Pediatric Lower Limb Deformities
S Sabharwal
2016

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 37 patents
Referenced in 1 clinical guideline sources
221 readers on Mendeley
1 readers on CiteULike
See more details